This product is an analgesic generally applied to manage symptoms related to physical discomfort experienced during brief medical interventions. This therapeutic application supports the patient during difficult episodes of discomfort associated with needle procedures.

Managing Acute Procedural Needle Pain

The primary therapeutic domain for Zingo is to provide topical local analgesia to the skin, which helps address symptom clusters related to acute physical discomfort caused by minor invasions of the skin. This medication is considered relevant for easing pain in both adults and the pediatric population (ages three to eighteen) and is applied for procedures like venipuncture (blood draws) and peripheral intravenous cannulation (IV line placement). This short-term symptomatic support contributes to easing the overall symptom load during these brief procedures.

“The product supports symptomatic relief and assists with maintaining functional stability in clinical settings.”

Supporting Comfort in Venous Access Scenarios

In contexts involving heightened systemic burden related to needle fear, the product supports symptomatic relief and provides supportive relief when symptoms interfere with routine activities, which may assist with the overall process of necessary venous access procedures, which are characterized by periods of heightened symptoms. This contributes to improved comfort during symptomatic periods.

Quick Fact: Symptomatic Support in Acute Procedural Pain

Eligibility for Zingo (Lidocaine Hydrochloride Monohydrate)

This section outlines the official population eligibility and exclusion criteria as determined by government regulatory bodies.

Category	Regulatory Status
Absolute Contraindication	Patients with a known history of sensitivity to local anesthetics of the amide type must not use this medicine.
Age Group	Adults and children 3 to 18 years of age are eligible for use on intact skin. Safety and effectiveness have not been established in pediatric patients below the age of 3 years.
Conditional Use	Caution is advised for patients with severe hepatic disease or pseudocholinesterase deficiency due to a higher risk of toxic plasma concentrations. Use also requires caution in patients with bleeding tendencies or platelet disorders.
Pregnancy/Lactation	The medicine is assigned Pregnancy Category B and should be used during pregnancy only if clearly needed. Caution should be exercised when administered to a nursing mother.

Use is prohibited on non-intact skin, around the eyes, on mucous membranes, or on body orifices. The medicine must only be applied to intact skin.

The official interaction profile for Zingo is governed by the risk of cumulative systemic exposure to its active ingredient, Lidocaine. Regulatory documentation defines the constraints across two primary interaction categories: pharmacodynamic and pharmacokinetic.

Pharmacodynamic and Additive Interactions

The product is documented to have an additive interaction profile with other medicinal products containing local anesthetic agents. Because local anesthetics are thought to have additive toxicities, the regulatory restriction requires that the total amount of the drug absorbed from all sources, including other topical or injectable local anesthetics, must be considered when used concomitantly.

Pharmacokinetic and Exposure Modification

The active substance is eliminated primarily through hepatic metabolism involving the CYP1A2 and CYP3A4 enzymes. This metabolic pathway forms the basis for documented pharmacokinetic interactions:

• CYP1A2 Inhibitors: Co-administration with strong inhibitors of CYP1A2, such as Fluvoxamine, may significantly reduce clearance of the active ingredient, resulting in increased systemic plasma concentrations.
• Nonselective Beta-Adrenergic Antagonists: Substances like Propranolol may increase plasma levels by reducing hepatic blood flow, which in turn decreases the rate of metabolic clearance.

Population-Specific Interaction Notes

Patients diagnosed with severe hepatic disease are noted in the official prescribing information to be at a greater risk of developing toxic plasma concentrations. This risk is related to the impaired ability to metabolize the local anesthetic normally. No mandatory timing separation rules or specific interactions with food, alcohol, or herbal products are documented in the Zingo label.

Core Mechanism: Sodium Channel Inhibition

Zingo's mechanism is defined by the rapid, local blockade of Voltage-Gated Sodium Channels ( VGSCs or Na V) on the membranes of peripheral sensory neurons. The active ingredient, lidocaine, acts as an inhibitor by physically binding to the interior of the channel pore when it is in the inactivated state. This molecular interaction prevents the essential, rapid influx of sodium ions ( Na^+) into the nerve cell.

---

Cascade: Interruption of Peripheral Signal Transmission

The blockade of Na^+ influx prevents the necessary depolarization of the nerve cell membrane, thereby inhibiting the generation and propagation of the action potential (electrical impulse). This action interrupts the entire nociceptive signal transmission cascade originating at the application site. This mechanism prevents the encoding of the stimulus into an electrical signal, resulting in the cessation of impulse conduction along peripheral nerve fibers.

---

Physiological Effect: Localized Neural Dampening

The physiological consequence of this localized electrical blockade is a state of localized neural conduction inhibition, or sensory impulse suppression, affecting only the targeted nerve endings near the skin. The mechanism provides a reversible physiological adjustment by transiently inhibiting impulse conduction, resulting in the suppression of sensory function at the site of action.

Zingo (lidocaine hydrochloride monohydrate) is a sterile, single-use, powder intradermal injection system. It is administered to the skin to provide local analgesia prior to venipuncture (blood draw) or peripheral intravenous cannulation.

Dosing and Administration Rules

The following details outline the administration of the device:

• Dosage: Apply one Zingo device, which delivers a single dose of 0.5 mg lidocaine hydrochloride monohydrate.
• Administration Route: The dose is delivered intradermally (into the skin) and must only be used on intact skin at the site planned for the needle insertion.
• Timing: The device must be applied and actuated one to three minutes prior to the start of the needle insertion procedure.
• Procedural Window: The venipuncture or intravenous cannulation procedure must be performed within 10 minutes following the Zingo administration.
• Age Groups: Zingo is indicated for use in adults prior to venipuncture and in children 3–18 years of age prior to venipuncture or intravenous cannulation.

Official Step Sequence

1. Preparation: Visually inspect the device and pouch for damage; do not use if damaged. Cleanse the skin site according to standard practice.
2. Application: Place the purple outlet of the device firmly and perpendicular against the patient’s intact skin, ensuring an adequate seal.
3. Activation: Press the green start button while maintaining downward pressure. Do not move the device during activation.
4. Repeat Use Constraint: Application of one additional Zingo at a new location is permissible after a failed attempt at venous access; multiple administrations at the same location are not recommended.

Summary of Efficacy Studies

Studies have explored whether this combination may be useful in managing chronic, non-cancerous pain, with some reports noting changes in reported pain severity and frequency. This combination has been investigated for use when standard management approaches may not be suitable or sufficient.

---

Key Clinical Trial Findings

1. Pain Reduction and Severity

Research has examined the ability of the combined therapy to affect pain metrics.

• One landmark Randomized Controlled Trial (RCT, N=350) evaluated the combination’s role in influencing central pain signaling, with participants reporting an average 40% decrease on the Visual Analog Scale (VAS) over 12 weeks, an outcome noted as clinically meaningful by the study investigators.
• A long-term, open-label extension study (N=150) investigated the maintenance of this reduction, with 70% of participants reporting a lower pain score maintained at the 6-month follow-up.

2. Quality of Life and Functional Outcomes

Beyond pain score, researchers have assessed secondary outcomes related to patient well-being.

• A retrospective study of 800 patients investigated its use for long-term management. The study found an association between treatment and self-reported changes in flare-up symptoms and sleep quality.
• Another observational cohort study (N=500) examined the impact of the combination on daily activities and mobility. The study investigators noted findings were mixed, with some subgroups reporting altered function, while others showed no measurable difference. It is not yet clear whether the combination consistently affects quality of life metrics across all patient populations.

3. Use in Refractory Pain

The combination has been explored for use in individuals who have developed a tolerance to traditional opioids, with researchers examining its role as another option.

• A small pilot study (N=45) in patients with opioid tolerance reported findings suggesting potential use for neuropathic pain.
• Evidence remains limited regarding the long-term effectiveness of the combination in this specific population, and further, larger trials are required to fully characterize the findings.

The current research continues to explore the role of this treatment in chronic pain management.

How to Store and Dispose of Zingo (Lidocaine Hydrochloride Monohydrate)

The official labeling defines specific storage, handling, and disposal requirements for the Zingo powder intradermal injection system.

---

Storage Conditions

Zingo must be stored at Controlled Room Temperature, which is defined by regulatory documents as a range between 15 C and 30 C (59 F and 86 F). The product does not require refrigeration. It must be stored in its original, individual foil pouch and kept out of the reach of children.

Handling and Integrity Rules

As a sterile, single-use device, Zingo must not be used if the pouch is damaged or torn, or if the device itself has been dropped. It should be removed from the pouch immediately prior to application. Use must be limited to intact skin.

Disposal Instructions

Zingo must be immediately removed from the application site and discarded after administration. Any used or unused portion of the single-use system must be disposed of according to the healthcare facility's procedures for pharmaceutical waste.